[go: up one dir, main page]

NO20053592L - Water soluble phenylpyridazine derivatives and drugs containing them. - Google Patents

Water soluble phenylpyridazine derivatives and drugs containing them.

Info

Publication number
NO20053592L
NO20053592L NO20053592A NO20053592A NO20053592L NO 20053592 L NO20053592 L NO 20053592L NO 20053592 A NO20053592 A NO 20053592A NO 20053592 A NO20053592 A NO 20053592A NO 20053592 L NO20053592 L NO 20053592L
Authority
NO
Norway
Prior art keywords
water soluble
drugs containing
phenylpyridazine derivatives
derivatives
salt
Prior art date
Application number
NO20053592A
Other languages
Norwegian (no)
Other versions
NO20053592D0 (en
Inventor
Hiromichi Shigyo
Seiichi Sato
Yoshinori Kyotani
Tomoyuki Koshi
Takahiro Kitamura
Hideo Yoshizaki
Kyoko Yasuoka
Shunji Takemura
Junko Totsuka
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of NO20053592D0 publication Critical patent/NO20053592D0/en
Publication of NO20053592L publication Critical patent/NO20053592L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Et fenylpyridazin-derivat representert ved den generelle formel (1): (hvor, R1, R2, R3, X, Y, Z og n har samme betydning som definert i beskrivelsen); eller et salt derav og en medisin inneholdende derivatet eller saltet. Fenylpyridazin-derivatet har utmerket hemmende aktivitet mot interleukin-p-produksjon, og har høy vannoppløselighet og høy oral absorberbarhetA phenylpyridazine derivative represented by the general formula (1): (wherein, R1, R2, R3, X, Y, Z and n have the same meaning as defined in the specification); or a salt thereof and a drug containing the derivative or salt. The phenylpyridazine derivative has excellent inhibitory activity against interleukin β production, and has high water solubility and high oral absorbability.

NO20053592A 2003-03-18 2005-07-25 Water soluble phenylpyridazine derivatives and drugs containing them. NO20053592L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003073403 2003-03-18
PCT/JP2004/003487 WO2004083188A1 (en) 2003-03-18 2004-03-16 Water-soluble phenylpyridazine derivative and medicine containing the same

Publications (2)

Publication Number Publication Date
NO20053592D0 NO20053592D0 (en) 2005-07-25
NO20053592L true NO20053592L (en) 2005-11-30

Family

ID=33027793

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053592A NO20053592L (en) 2003-03-18 2005-07-25 Water soluble phenylpyridazine derivatives and drugs containing them.

Country Status (13)

Country Link
US (1) US7211577B2 (en)
EP (1) EP1604984A1 (en)
JP (1) JPWO2004083188A1 (en)
KR (1) KR20050113627A (en)
CN (1) CN1759103A (en)
AU (1) AU2004221966A1 (en)
BR (1) BRPI0408359A (en)
CA (1) CA2518227A1 (en)
MX (1) MXPA05009972A (en)
NO (1) NO20053592L (en)
RU (1) RU2005132167A (en)
TW (1) TW200510335A (en)
WO (1) WO2004083188A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004010207A1 (en) * 2004-03-02 2005-09-15 Aventis Pharma S.A. New 4-benzimidazolyl-3(2H)-pyridazinone derivatives are kinase inhibitors, especially useful for treatment of cancer
EP1941911A4 (en) * 2005-10-28 2011-01-12 Kowa Co METHOD FOR PREVENTING AND / OR TREATING RHEUMATOID ARTHRITIS
WO2014121942A1 (en) 2013-02-07 2014-08-14 Merck Patent Gmbh Macrocyclic pyridazinone derivatives
CA2900431C (en) * 2013-02-07 2021-05-04 Merck Patent Gmbh Pyridazinone-amides derivatives
FR3103701B1 (en) * 2019-11-28 2021-11-26 Inst Nat Sante Rech Med TYPEN2-ARYLMETHYL-4-HALOALKYL-PYRIDAZIN-3-ONE COMPOUNDS AND THEIR USE

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR206496A1 (en) 1972-07-03 1976-07-30 Riker Laboratories Inc PROCEDURE FOR THE PREPARATION OF 2-PHENOXY-4-NITRO-ALKYL OR HALOALKYLSULPHONANILIDES
JPH0753725B2 (en) * 1987-10-08 1995-06-07 富山化学工業株式会社 4H-1-benzopyran-4-one derivative and its salt, their production method and anti-inflammatory agent containing them
FI91062C (en) 1988-12-28 1994-05-10 Eisai Co Ltd Process for the preparation of naphthalene derivatives useful as a medicament
MX9300141A (en) 1992-01-13 1994-07-29 Smithkline Beecham Corp NOVEL IMIDAZOLE COMPOUNDS, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT.
ATE163412T1 (en) 1993-06-08 1998-03-15 Sanofi Sa PYRIDAZINE AS INTERLEUKIN-1-BETA CONVERSION ENZYME INHIBITORS
WO1997005878A1 (en) 1995-08-10 1997-02-20 Merck & Co., Inc. 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
EP0975604B1 (en) 1997-03-14 2004-07-21 Merck Frosst Canada & Co. Pyridazinones as inhibitors of cyclooxygenase-2
BR9812127A (en) 1997-08-22 2000-07-18 Abbott Lab Arylpyridazinones as inhibitors of prostaglein biosynthesis endoperoxide h synthase
WO1999010332A1 (en) 1997-08-22 1999-03-04 Abbott Laboratories Prostaglandin endoperoxide h synthase biosynthesis inhibitors
MXPA00004955A (en) * 1997-11-19 2002-10-17 Kowa Co Novel pyridazine derivatives and drugs containing the same as the active ingredient.
TWI241295B (en) * 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
HK1041876B (en) 1998-10-27 2006-06-23 Abbott Laboratories Prostaglandin endoperoxide h synthase biosynthesis inhibitors
JP2000247959A (en) 1999-02-26 2000-09-12 Kowa Co Pyridazin-3-one derivatives and pharmaceuticals containing the same
US6664256B1 (en) * 2000-07-10 2003-12-16 Kowa Co., Ltd. Phenylpyridazine compounds and medicines containing the same
MXPA04002939A (en) * 2001-09-26 2004-06-18 Kowa Co Water-soluble phenylpyridazine derivatives and drugs containing the same.
US6861428B2 (en) * 2001-09-26 2005-03-01 Kowa Co., Ltd. Water-soluble phenylpyridazine compounds and compositions containing the same
US7314877B2 (en) 2003-03-07 2008-01-01 Kowa Co., Ltd. Benzofuran derivative

Also Published As

Publication number Publication date
BRPI0408359A (en) 2006-03-21
WO2004083188A1 (en) 2004-09-30
AU2004221966A1 (en) 2004-09-30
NO20053592D0 (en) 2005-07-25
US20060142292A1 (en) 2006-06-29
EP1604984A1 (en) 2005-12-14
KR20050113627A (en) 2005-12-02
RU2005132167A (en) 2006-05-10
MXPA05009972A (en) 2005-11-04
JPWO2004083188A1 (en) 2006-06-22
CA2518227A1 (en) 2004-09-30
TW200510335A (en) 2005-03-16
US7211577B2 (en) 2007-05-01
CN1759103A (en) 2006-04-12

Similar Documents

Publication Publication Date Title
NO20054852L (en) GFAT inhibitors
JO2353B1 (en) Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
UA84712C2 (en) N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
WO2005021544A3 (en) N3-substituted imidazopyridine-derivatives as c-kit inhibitors
NO20035210D0 (en) 2-anilino-pyrimidine derivatives as cyclin-dependent kinase inhibitors
WO2006005609A3 (en) Substituted oxindol derivatives and medicaments containing the same
GEP20074152B (en) Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
TW200642689A (en) Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
UA94065C2 (en) Dihydropseudoerythromycin derivatives
NO20073551L (en) Nikotinacetylkolinreseptorligander
MY186650A (en) Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives
NO20070570L (en) Compounds.
NO20052683L (en) New pyridopyrimidinone compounds, processes for their preparation and pharmaceutical compositions containing them
WO2006100082A3 (en) Substituted oxindol derivatives, drugs containing said derivatives and the use thereof
SE0300908D0 (en) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
NO20050087L (en) N-benzoylureido-cinnamic acid derivatives, process for their preparation and use
NO20070089L (en) DPP-IV inhibitors
DE60327998D1 (en) PYRIMIDINE COMPOUNDS
NO20062453L (en) Thiozolidinones, their preparation and use as pharmaceuticals
GEP20104875B (en) Pyrimidine derivatives for the treatment of abnormal cell growth
NO20050667L (en) N-substituted-1H-indole-5-propionic acid compounds as PPAR agonists useful for the treatment of diabetes
NO20071616L (en) Benzoxazine and cinoxaline derivatives and uses
NO20053592L (en) Water soluble phenylpyridazine derivatives and drugs containing them.
MY139613A (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
TW200510370A (en) Urea derivatives

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application